Xintela extends patent protection for degenerative joint diseasesXintela today announced that the company's international patent application directed to the prevention and treatment of degenerative joint diseases using stem cells, including osteoarthritis, has been published. The data on which the patent application is based are derived from the horse study conducted by Xintela in late 2016. It demonstrated that stem cells, selected using Xintela's marker technology, protect both joint cartilage and underlying bone following a cartilage injury. The patent application extends patent protection for Xintela's stem cell product for the treatment of traumatic joint damage, which may be caused by a sport injury, for example. The stem cell product aims to prevent degradation of joint cartilage and inhibit development of bone sclerosis, which are typical disease related changes in a joint afflicted with osteoarthritis. The application also covers the use of Xintela's stem cell product for the treatment of degenerative joint diseases, including osteoarthritis and bone sclerosis.
"We are proactively working to broaden and strengthen our patent portfolio in both existing and new areas. In the horse study, we demonstrated that Xintela's selected stem cells have unique properties that make them suitable for both prevention and treatment of osteoarthritis and other degenerative joint diseases, "says Xintela's CEO, Evy Lundgren-Åkerlund.
The horse study was conducted together with a research group at Cornell University, USA, and will be published in an international scientific journal. The results form an important part of the preclinical documentation for Xintela's clinical studies in both humans and animals. 2018-08-09 Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: [email protected]
Medicon Village
223 81 Lund
www.xintela.se
For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: [email protected]
www.laika.se
The following documents can be retrieved from beQuoted
Xintela Pressrelease 2018-08-09 English.pdf About Xintela
Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has recently established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK® is used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against specific tumors with first focus on the aggressive brain tumor glioblastoma. Positive preclinical results from cell studies and animal model have shown that the ADC treatment has a targeting and killing effect on specific tumor cells supporting further development of the company's oncology business. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 